Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Type IIa hyperlipidaemia, Upper-airway cough syndrome, Vitamin D deficiency
Clinical narrative: Non STEMI myocardial infarction; Left sided weakness; Microscopic Hematuria/ Gross hematuria; Upper airway cough syndrome/ Cough; COVID-19 virus infection; Tremor; OSA(Obstructive sleep apnea); BPH with obstruction/ lower urinary tract symptoms; Vitamin D deficiency; Morbid obesity; Pure hypercholesterolemia; This spontaneous case was reported by a patient and describes the occurrence of ACUTE MYOCARDIAL INFARCTION (Non STEMI myocardial infarction) and HEMIPARESIS (Left sided weakness) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient had type 2 diabetes mellitus with microalbuminuria, with long term current use of insulin, type 2 diabetes mellitus with cardiac complication,type 2 diabetes mellitus with hyperglycemia, with long term current use of insulin, type 2 diabetes mellitus with retinopathy, with long term current use of insulin.  Concurrent medical conditions included Penicillin allergy since 1960, Drug allergy (Gabapentin), Allergy to antibiotic (Clarithromycin), Fish allergy, Allergy to chemicals (Monosodium  Glutamate), Drug allergy (Opioid  analgesics), Food allergy (Pork), Drug allergy (Sulfa), Diabetic foot infection (Diabetic toe bone infection), Type 2 diabetes mellitus (Uncontrolled type 2 diabetes mellitus with complications (microalbuminuria, cardiac complication, Hyperglycemia, retinopathy with long term current use of insulin)) and Hypertension (Essential hypertension). Concomitant products included INSULIN for Type 2 diabetes mellitus, INFLUENZA VACCINE (FLU VACCINE VII) for an unknown indication.    On 28-Jun-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACUTE MYOCARDIAL INFARCTION (Non STEMI myocardial infarction) (seriousness criterion medically significant), HEMIPARESIS (Left sided weakness) (seriousness criterion medically significant), HAEMATURIA (Microscopic Hematuria/ Gross hematuria), UPPER-AIRWAY COUGH SYNDROME (Upper airway cough syndrome/ Cough), COVID-19 (COVID-19 virus infection), TREMOR (Tremor), OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA(Obstructive sleep apnea)), BENIGN PROSTATIC HYPERPLASIA (BPH with obstruction/ lower urinary tract symptoms), VITAMIN D DEFICIENCY (Vitamin D deficiency), OBESITY (Morbid obesity) and TYPE IIA HYPERLIPIDAEMIA (Pure hypercholesterolemia). The patient was treated with LINEZOLID (ZYVOX) (oral) ongoing from 15-Nov-2022 for Diabetic foot infection, at a dose of 6 weeks. At the time of the report, ACUTE MYOCARDIAL INFARCTION (Non STEMI myocardial infarction), HEMIPARESIS (Left sided weakness), HAEMATURIA (Microscopic Hematuria/ Gross hematuria), UPPER-AIRWAY COUGH SYNDROME (Upper airway cough syndrome/ Cough), COVID-19 (COVID-19 virus infection), TREMOR (Tremor), OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA(Obstructive sleep apnea)), BENIGN PROSTATIC HYPERPLASIA (BPH with obstruction/ lower urinary tract symptoms), VITAMIN D DEFICIENCY (Vitamin D deficiency), OBESITY (Morbid obesity) and TYPE IIA HYPERLIPIDAEMIA (Pure hypercholesterolemia) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Aug-2022, C-reactive protein: 5.2 milligram per litre High. On 11-Aug-2022, Haematocrit: 38.3 % low. On 11-Aug-2022, Haemoglobin: 12.3  low. On 11-Aug-2022, Mean cell haemoglobin concentration: 32.1 g/dL low. On 11-Aug-2022, Metabolic function test: 179 mg/dl Glucose  High. On 11-Aug-2022, Red blood cell count: 4.18  low. On an unknown date, Prostatic specific antigen: Elevated.    Patient received COVID-19 vaccine 3 booster for Moderna series.  Patient was prescribed with antibiotics Zyvox and it should be taken exactly as prescribed even if patient felt better also, doses could not be skipped or stop the antibiotics early without approval from the doctor.  Company comment: This spontaneous case concerns a adult male patient, with medical condition of type 2 diabetes mellitus with microalbuminuria, cardiac complication, Hyperglycemia, retinopathy with long term current use of insulin, who experienced the unexpected serious (medically significant) event of Acute myocardial infarction and Hemiparesis and other non-serious events that occurred on unspecified day after third dose with of mRNA-1273 vaccine. The patient was treated with LINEZOLID (ZYVOX) (oral) ongoing from 15-Nov-2022 for Diabetic foot infection. The events outcome had not resolved. Patient elderly age with pre-existing medical condition remains confounder for the events. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns a adult male patient, with medical condition of type 2 diabetes mellitus with microalbuminuria, cardiac complication, Hyperglycemia, retinopathy with long term current use of insulin, who experienced the unexpected serious (medically significant) event of Acute myocardial infarction and Hemiparesis and other non-serious events that occurred on unspecified day after third dose with of mRNA-1273 vaccine. The patient was treated with LINEZOLID (ZYVOX) (oral) ongoing from 15-Nov-2022 for Diabetic foot infection. The events outcome had not resolved. Patient elderly age with pre-existing medical condition remains confounder for the events. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.